MAPT and Alzheimer disease: In clinical studies, the Aβ1﻿–42/Aβ1﻿–38 ratio has been capable of significantly discriminating AD from other forms of dementia [30–32] and shown to be negatively correlated with CSF p-tau levels in AD patients [31].